SCHEMBL4282163

SCHEMBL4282163

Cc1ccc(C)c(-c2cc(Cl)nc(N)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 10/20 0.54
HSP90AB1 P08238 10/20 0.54
AGPAT2 O15120 8/20 0.51
KDM4E B2RXH2 1/20 0.49
CDC7 O00311 1/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
PIM1 P11309 1/20 0.43
PRKACA P17612 1/20 0.43
GRK5 P34947 1/20 0.43
MAP2K2 P36507 1/20 0.43
MAPK8 P45983 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43
CLK2 P49760 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CDK7 P50613 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282884 0.87 AGPAT2 (0.67) HSP90AA1HSP90AB1AGPAT2KDM4E
SCHEMBL2849100 0.84 AGPAT2 (0.64) HSP90AA1HSP90AB1AGPAT2KDM4ECDC7
SCHEMBL4286576 0.84 AGPAT2 (0.64) HSP90AA1HSP90AB1AGPAT2KDM4E
SCHEMBL4289224 0.84 AGPAT2 (0.64) HSP90AA1HSP90AB1AGPAT2KDM4E
SCHEMBL4288458 0.81 HSP90AA1 (0.76) HSP90AA1HSP90AB1AGPAT2KDM4EDYRK1A
SCHEMBL29571104 0.81 HSP90AA1 (0.70) HSP90AA1HSP90AB1AGPAT2KDM4ECDC7
SCHEMBL3952089 0.81 HSP90AA1 (0.70) HSP90AA1HSP90AB1AGPAT2KDM4ECDC7
SCHEMBL15757474 0.79 NUDT1 (0.64) AGPAT2ROCK1CLK4
SCHEMBL3451558 0.77 HSP90AB1 (0.68) HSP90AA1HSP90AB1KDM4E
SCHEMBL13880247 0.77 AGPAT2 (0.87) AGPAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT HSP90AA1 4126/4885HSP90AB1 4236/4885AGPAT2 100/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT HSP90AA1 4006/4885HSP90AB1 3829/4885AGPAT2 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.